Abstract
Purpose
2-Deoxy-2-[F-18]fluoro-d-glucose (FDG)-positron emission tomography (PET) has an established role in restaging of various cancers, including papillary and undifferentiated thyroid carcinoma. However, controversies exist regarding its ability to reliably assess recurrent medullary thyroid cancer (MTC). We were therefore prompted to review our experience with FDG-PET for detection of occult MTC.
Methods
This is a retrospective study (Apr 1, 1997–Mar 31, 2004) of 13 patients with histologic diagnosis of MTC, who had PET examinations. The group included six men and seven women, 15–62 years old (average: 48 ± 13). The PET scan request was triggered by rising levels of calcitonin and negative anatomical imaging studies.
Results
Recurrent/metastatic disease was identified by PET in seven (54%) of the 13 patients. The lesions were located in superior mediastinum (4), cervical lymph nodes (3), thyroid bed (2), lung (1) and liver (1). The calcitonin levels ranged from 52 to 5,090 pg/ml (average: 1,996 pg/ml) in patients with negative PET scans and from 132 to 9,500 pg/ml (average: 3,757 pg/ml) in patients with positive studies. The sensitivity and specificity of FDG-PET for disease detection in this cohort were 85.7% (95% CI: 48.7–97.4) and 83.3 % (95 % CI: 43.6–96.9), respectively.
Conclusion
Our findings suggest a significant role for FDG-PET in patients with suspected MTC recurrence, with sensitivity of 85.7% and specificity of 83.3% for disease detection. FDG-PET provides additional information in a significant fraction of cases (54%) and could be used for restaging of patients with MTC and elevated levels of biomarkers (calcitonin). Additional studies are necessary to further evaluate the role of FDG-PET in MTC.
Similar content being viewed by others
References
Jemal A, Siegel A, Ward E, Murray T, Xu J, Smigal C, et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130 (Mar–Apr)
Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428 (Nov)
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1057 (Dec)
O’Riordain DS, O’Brien T, Weaver AL, Gharib H, Hay ID, Grant CS, et al. (1994) Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116:1017–1023 (Dec)
Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 48:265–273 (Mar)
Musholt TJ, Musholt PB, Dehdashti F, Moley JF (1997) Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 122:1049–1060; discussion 1060–1061 (Dec)
Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA (1999) Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9:797–804 (Aug)
Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR (1996) PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol 23:717–735 (Aug)
Gasparoni P, Rubello D, Ferlin G (1997) Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 20:527–530 (Oct)
Rufini V, Salvatori M, Garganese MC, Di Giuda D, Lodovica Maussier M, Troncone L (2000) Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 25:273–282 (Apr–Jun)
de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT (2004) Impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11:786–794 (Aug)
Adalet I, Kocak M, Oguz H, Alagol F, Cantez S (1999) Determination of medullary thyroid carcinoma metastases by 201Tl, 99Tcm(V)DMSA, 99Tcm-MIBI and 99Tcm-tetrofosmin. Nucl Med Common 20:353–359 (Apr)
Ugur O, Kostakglu L, Guler N, Caner B, Uysal U, Elahi N, et al. (1996) Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 23:1367–1371 (Oct)
Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A (2000) The value of F-18 FDG PET in patients with medullary thyroid cancer. Eur J Nucl Med 27:490–496 (May)
Crippa F, Alessi A, Gerali A, Bombardieri E (2003) FDG-PET in thyroid cancer. Tumori 89:540–543 (Sep–Oct)
Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E (2001) 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64–71 (Jan)
Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671–1676 (Nov.)
Li S, Beheshti M (2005) The radionuclide molecular imaging and therapy of neuroendocrine tumors. Current Cancer Drug Targets 5:139–148 (Mar)
Gotthardt M, Battmann A, Hoffken H, Schurrat T, Pollum H, Beuter D, et al. (2004) 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nucl Med Commun 25:439–443 (May)
Bockisch A, Brandt-Mainz K, Gorges R, Muller S, Stattaus J, Antoch G (2003) Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 30:22–25 (May)
Szakall S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. (2002) 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66–71 (Jan)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Iagaru, A., Masamed, R., Singer, P.A. et al. Detection of Occult Medullary Thyroid Cancer Recurrence with 2-Deoxy-2-[F-18]fluoro-d-glucose-PET and PET/CT. Mol Imaging Biol 9, 72–77 (2007). https://doi.org/10.1007/s11307-006-0072-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-006-0072-1